A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and effective the study drug(s) are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) is in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could mak

Trial Details

NCT ID
NCT06413680
Phase
PHASE1 / PHASE2
Sponsor
Regeneron Pharmaceuticals
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • REGN10597
  • Cemiplimab
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • North Haven, Connecticut, United States|41.39093,-72.85954
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Grand Rapids, Michigan, United States|42.96336,-85.66809

Key Eligibility Criteria

  • Dose escalation cohorts:
  • 1\. Histologically or cytologically confirmed diagnosis of solid malignancy (locally advanced or metastatic) with confirmed progression on standard…
  • Dose expansion cohorts:
  • 1\. Histologically of cytologically confirmed diagnosis of one of the following tumors with criteria, as defined in the protocol:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →